Paper Details

  1. Home
  2. Paper Details

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Author: Aguado de la RosaCarlos, AguilarAndrés, BarnetoIsidoro, BenítezRaquel, BernabéReyes, Bosch-BarreraJoaquim, CalvoVirginia, CampsCarlos, Casal-RubioJoaquín, CoboManuel, Cruz-BermúdezAlberto, González-LarribaJosé L, Hernando-TranchoFlorentino, InsaAmelia, López VivancoGuillermo, López-CastroRafael, Martín-LópezJavier, Martínez-MartíAlex, MassutiBartomeu, MoránTeresa, MosqueraJoaquín, NadalErnest, PalmeroRamón, PonceSantiago, ProvencioMariano, ReguartNoemí, Rodríguez-AbreuDelvys, RomeroAtocha, Serna-BlascoRoberto, de CastroJavier

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A phase 2 trial of 86 patients with resectable stage IIIA or IIIB non-small-cell lung cancer (NSCLC) found that neoadjuvant nivolumab plus platinum-based chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Approximately 20% of patients with non-small-cell lung cancer (NSCLC) receive a diagnosis of stage III disease. There is no current consensus regarding the most appropriate treatment for these patients. METHODS: In this open-label, phase 2 trial, we randomly assigned patients with resec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa2215530

データ提供：米国国立医学図書館（NLM）

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

This study, like a dedicated team of engineers constructing a complex bridge, explores the efficacy of perioperative nivolumab and chemotherapy in treating stage III non-small-cell lung cancer (NSCLC). The authors, like skilled architects, meticulously design and conduct a Phase 2 trial to evaluate the impact of this combined treatment approach on patient outcomes. Their research, like a meticulously constructed blueprint, reveals the potential of nivolumab and chemotherapy to improve pathological complete response rates, progression-free survival, and overall survival in these patients. The study concluded that perioperative treatment with nivolumab plus chemotherapy resulted in a higher percentage of patients with a pathological complete response and longer survival than chemotherapy alone.

A Bridge to Better Outcomes for Lung Cancer Patients

This research offers a promising new approach for treating stage III NSCLC, a condition that can be challenging to manage. The study's findings, like a sturdy bridge spanning a deep chasm, offer hope for better outcomes and potentially longer survival for these patients. This research, like a valuable gem unearthed in a desert, has the potential to revolutionize lung cancer treatment.

Navigating the Lung Cancer Landscape

Lung cancer, like a vast and unforgiving desert, can be a daunting challenge. Understanding the various treatment options available, including the potential benefits of perioperative nivolumab and chemotherapy, can empower individuals to actively participate in their care and make informed decisions about their treatment plans. This research serves as a valuable resource for patients and their families seeking to navigate the complex landscape of lung cancer.

Dr.Camel's Conclusion

This study highlights the importance of research and innovation in finding effective treatment strategies for challenging diseases. The authors' dedication to improving patient outcomes in lung cancer is commendable. It's a reminder that even in the seemingly intractable desert of cancer treatment, there is always hope for progress and improvement.

Date :
  1. Date Completed 2023-08-27
  2. Date Revised 2023-10-18
Further Info :

Pubmed ID

37379158

DOI: Digital Object Identifier

10.1056/NEJMoa2215530

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.